跳至主要内容
临床试验/ITMCTR2000003424
ITMCTR2000003424招募中1 期

An exploratory study on the treatment of stage III colon cancer with special prescription of removing dampness and removing dampness after postoperative chemotherapy

Oncology Department, Guangdong Provincial Hospital of Chinese Medicine0 个研究点开始时间: 待定最近更新:
适应症

试验速览

阶段
1 期
状态
招募中
发起方

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional study

入排标准

年龄范围
18 至 75(—)
性别
All

入选标准

  • 1. Patients with colon cancer confirmed by histopathology or cytopathology;
  • 2. Patients who have undergone radical surgery and whose postoperative pathological stage is stage III and T4 or N2 (according to NCCN clinical practice guideline colorectal cancer (2018 V4) standard);
  • 3. Adjuvant chemotherapy has been completed (for example, 4-8 XELOX, 6-12 FOLFOX, or fluorouracil single drug chemotherapy has been completed, and no adjuvant chemotherapy will be accepted in the near future);
  • 4. The patients without recurrence and metastasis were reexamined in the past 1 month;
  • 5. Patients whose last chemotherapy time was less than 3 months;
  • 6. Patients with PS score (ECoG) <= 2;
  • 7. Patients aged 18-75 years;
  • 8. Patients with normal liver and kidney function;
  • Normal renal function: serum creatinine <= 1.5mg/dl (133 µ mol / L) and creatinine clearance >= 60ml / min;
  • Normal liver function: total serum bilirubin level <= 1.5 times of upper limit of normal value (ULN), serum AST and ALT 2.5 times of ULN;
  • 9. The patients who sign the informed consent and are willing to receive the treatment of this program, can insist on taking medicine and have good compliance.

排除标准

  • 1. Patients who are unable to complete the baseline assessment form;
  • 2. Patients with ileus or incomplete ileus;
  • 3. Patients with other serious diseases, including uncontrolled active infection, severe electrolyte disorder, and obvious bleeding tendency;
  • 4. Pregnant and lactating women;
  • 5. Patients with autoimmune diseases and blood system diseases, or long-term use of hormone or immunosuppressant;
  • 6. Patients with other uncontrolled tumors;
  • 7. Patients who have received new adjuvant or adjuvant radiotherapy, or intend to receive radiotherapy;
  • 8. Patients with serious brain disease or mental disease that affect the ability of self-report;
  • 9. Have a history of organ transplantation (including bone marrow autotransplantation and peripheral stem cell transplantation);
  • 10. Patients without legal capacity, and those who are affected by medical or ethical reasons.

研究者

发起方
Oncology Department, Guangdong Provincial Hospital of Chinese Medicine

相似试验

An exploratory study on the treatment of stage III... | 临床试验